Jasper Therapeutics
Jasper Therapeutics, based in Redwood City, CA, focuses on developing briquilimab, a monoclonal antibody aimed at treating various chronic and stem cell diseases.
Services
Jasper Therapeutics specializes in developing innovative therapeutic solutions for chronic mast and stem cell diseases. The company's flagship product, briquilimab, a monoclonal antibody targeting c-Kit (CD117), is at the core of their treatment offerings. Their mission revolves around providing safer and potentially curative therapies for patients suffering from serious and life-threatening conditions.
Products
Jasper Therapeutics' primary product is briquilimab, a monoclonal antibody targeting c-Kit (CD117). Biquilimab is being studied for its potential use in treating chronic urticaria, myelodysplastic syndromes (MDS), and as a conditioning agent for stem cell transplants in diseases such as sickle cell disease (SCD), Fanconi anemia (FA), and severe combined immunodeficiency (SCID).
Clinical Pipeline
Jasper Therapeutics maintains a robust clinical pipeline, with briquilimab undergoing extensive evaluation in multiple clinical trials. These trials focus on its efficacy for chronic and life-threatening conditions. The potential applications of briquilimab include treating chronic urticaria, myelodysplastic syndromes (MDS), as well as serving as a crucial component in the conditioning process for stem cell transplants required for sickle cell disease (SCD), Fanconi anemia (FA), and severe combined immunodeficiency (SCID).
Company Mission
Jasper Therapeutics is committed to making safer and potentially curative therapies accessible to a broader range of patients in need. Their mission is to advance the quality of life and treatment outcomes for individuals suffering from various chronic and life-threatening conditions through the development of innovative medical solutions.